UroGen Pharma (NASDAQ:URGN) Receives “Buy” Rating from HC Wainwright
UroGen Pharma (NASDAQ:URGN – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $64.00 price objective on the stock. URGN has been the topic of several other reports. D. Boral Capital reiterated a […]
UroGen Pharma (NASDAQ:URGN – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $64.00 price objective on the stock. URGN has been the topic of several other reports. D. Boral Capital reiterated a […]
